Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved

Q4 2025 Management View Jennifer Good, CEO, reported that "2025 was a major inflection point for growth at Trevi, driven by our positive data readouts in both the CORAL trial in patients with ...

Trevi Therapeutics Q4 Earnings Call Highlights

Trevi Therapeutics (NASDAQ:TRVI) used its fourth-quarter and year-end 2025 earnings call to outline next steps following what management described as a pivotal year driven by positive clinical data in ...

Tyvaso IPF Data In NEJM Reframes United Therapeutics Growth Potential

United Therapeutics (NasdaqGS:UTHR) reported full Phase 3 TETON-2 trial data for nebulized Tyvaso in idiopathic pulmonary ...

Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough Control

Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...
The American Journal of Managed Care

FDA and European Commission Grant Orphan Drug Status to Deupirfenidone for IPF

Orphan status in the U.S. can confer clinical-trial tax credits, user-fee exemptions, and up to seven years of post-approval market exclusivity for rare-disease programs. As a deuterated form of ...
Rutland Herald

Baseimmune Announces Strategic Expansion into Fibrosis with Lead Program Targeting Idiopathic Pulmonary Fibrosis (IPF)

The complex and redundant biology underlying fibrosis is widely believed to contribute to the limited effectiveness of single-target approaches. “Fibrosis is a biologically complex, organ-specific ...
Kaleido Scope

Learn More About IPF

What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...
Kaleido Scope

The Diagnosis of IPF

IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...
MarketWatch

First IPF Biomarker Clears Initial FDA Step Toward Qualification

The MarketWatch News Department was not involved in the creation of this content. CHICAGO, Dec. 22, 2025 /PRNewswire/ -- The Prognostic Lung Fibrosis Consortium (PROLIFIC), a collaborative consortium ...
The American Journal of Managed Care

Differentially Expressed Genes May Serve as IPF Biomarkers

Cellular senescence contributes to IPF progression by promoting inflammation and disrupting immune homeostasis. Four key genes—CDKN2A, VEGFA, SOX2, and FOXO3—were identified as differentially ...
Medscape

How to Integrate Palliative Care into IPF Treatment Plans

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...
Forbes

IPF: New Approach May Hold Potential For Treating This Fatal Lung Condition

Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. This article is more than 6 years old. Idiopathic pulmonary ...